Research Paper Volume 13, Issue 2 pp 2959—2981
A novel five-lncRNA signature panel improves high-risk survival prediction in patients with cholangiocarcinoma
Figure 3. Prognostic evaluation of the five-lncRNA signature in CCA patients in the WMU cohort. (A) Primer sequence of five-lncRNA markers; (B) KM curve analysis of OS validated the prognostic differences between high and low-risk groups in the WMU cohort; (C) ROC curve analysis of 3-year survival validated the reliability of five-lncRNA model.